UChicago study finds lasofoxifene a promising treatment for resistant breast cancer
A drug originally developed for osteoporosis could provide a more effective treatment for people with therapy-resistant ER-positive metastatic breast cancer than the current standard of care, with fewer unwanted side effects
In a study carried out in mice at the University of Chicago, researchers found that lasofoxifene outperformed fulvestrant, the current gold-standard drug, in reducing or preventing primary tumor growth. It also was more effective at preventing metastasis in the lung, liver, bone and brain, the four most common areas for this cancer to spread.
Additionally, while fulvestrant and similar drugs often cause unwanted, menopausal-like side effects, lasofoxifene prevents some of these symptoms. The research was published on May 13 in END
Additionally, while fulvestrant and similar drugs often cause unwanted, menopausal-like side effects, lasofoxifene prevents some of these symptoms. The research was published on May 13 in END